Skip to content

The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis

The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Evaluating Sepsis Patient's Disease Severity and Prognosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03340649
Enrollment
90
Registered
2017-11-13
Start date
2017-11-09
Completion date
2018-03-01
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

To observe the changes of plasma hepatocyte growth factor and soluble receptor s-Met levels in patients with sepsis, and to explore its clinical significance.

Detailed description

90 patients who diagnosed as sepsis were included in this study. Then keep blood samples from these patients in the first day, the third day, detect the hepatocyte growth factor and soluble receptor s-Met level in plasma byenzyme-linked immuno sorbent assay. Record Severity of illness and survival status of every patient within 28 days. Objective to evaluate the correlation between the level of hepatocyte growth factor and soluble receptor s-Met in plasma and the prognosis of the patients.

Interventions

taking peripheral blood of no more than 3ml

Sponsors

Jingyuan,Xu
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients admitted to ICU diagnosed of sepsis(sepsis3.0 criteria) 2. Patients signing informed consent

Exclusion criteria

1. Age is less than 18 years old or more than 80 years old 2. Pregnant women 3. Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome 4. Prothrombin time is extension in patients with after liver transplantation 5. Patients with chronic renal failure 6. Patients after kidney transplantation

Design outcomes

Primary

MeasureTime frameDescription
mortality28-day28-day mortality

Countries

China

Contacts

Primary Contactchenglong liang, master
15261893562@163.com15261893562
Backup Contactyi yang, doctor
yiyiyang2004@163.com+8602583262550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026